Moderate to Severe Crohn's Disease
Conditions
Brief summary
The purpose of the study is to assess the safety and tolerability of daily intravenous NI-0401 treatment, compared to matching placebo. And to assess the ability of NI-0401 to modulate the CD3 complex on T-cells.
Interventions
BIOLOGICALNI-0401 (anti-CD3 mAB)
0.05 mg up to 10 mg
DRUGPlacebo
Placebo
Sponsors
Light Chain Bioscience - Novimmune SA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Main Inclusion Criteria: 1. Men and women between 18 and 70 years of age. 2. Crohn's Disease Activity Index (CDAI) between 220 and 450. 3. Raised plasma CRP level. 4. Endoscopic inflammation. 5. Crohn's disease of at least 6 months duration, with colitis, ileitis, or ileocolitis, confirmed by endoscopy and histology within 28 days of study day 1. Main
Exclusion criteria
1. Have received or are planned to receive immunization with a live vaccine within 6 weeks prior to receiving study drug and 12 weeks after treatment cessation. 2. Concomitant disease: * Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurological or cerebral disease (including a history of seizure disorders or ongoing chronic active conditions such as chronic active hepatitis) * Previous diagnosis of, or known, malignancies * Severe infections, such as hepatitis, pneumonia or pyelonephritis, in the past three months. Less serious infections in the past 3 months, such as acute upper respiratory tract infection (colds) or uncompliant urinary tract infection are permitted at the discretion of the investigator * Active infection requiring antibiotic therapy * Serum anti HCV positive, serum HBsAg positive, serum anti-HIV positive * History of opportunistic infections such as herpes zoster within 2 months prior to screening, evidence of acute CMV or EBV, active Pneumocystic Carinii * History of active tuberculosis (TB) or currently undergoing treatment for TB. Patients with a positive TB skin test or chest x-ray are ineligible. Patients with a history of bacille Calmette Guerin (BCG) vaccination and a newly positive TB skin test or a chest X-ray showing fibrotic lesions consistent with previous TB are ineligible. The PPD skin test must be read between 48 and 72 hours * Stool examination positive for enteric pathogens, pathogenic ova or parasites, or Clostridium Difficile toxin within 4 weeks prior to Study Day 1
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability of intravenous NI-0401 . | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Immunological response defined as the percent change in the modulation of the CD3 complex on T-cells | — |
Outcome results
None listed